WO2000075298A3 - Molecules pour la detection et le traitement de maladies - Google Patents

Molecules pour la detection et le traitement de maladies Download PDF

Info

Publication number
WO2000075298A3
WO2000075298A3 PCT/US2000/015344 US0015344W WO0075298A3 WO 2000075298 A3 WO2000075298 A3 WO 2000075298A3 US 0015344 W US0015344 W US 0015344W WO 0075298 A3 WO0075298 A3 WO 0075298A3
Authority
WO
WIPO (PCT)
Prior art keywords
mddt
provides
disease detection
treatment
molecules
Prior art date
Application number
PCT/US2000/015344
Other languages
English (en)
Other versions
WO2000075298A8 (fr
WO2000075298A2 (fr
Inventor
David M Hodgson
Stephen E Lincoln
Frank D Russo
Peter A Spiro
Steven C Banville
Shawn R Bratcher
Gerard E Dufour
Howard J Cohen
Bruce H Rosen
Michael S Chalup
Jennifer L Hillman
Anissa Lee Jones
Jimmy Y Yu
Lila B Greenawalt
Scott R Panzer
Ann M Roseberry
Rachel J Wright
Susan E Daniels
Original Assignee
Incyte Genomics Inc
David M Hodgson
Stephen E Lincoln
Frank D Russo
Peter A Spiro
Steven C Banville
Shawn R Bratcher
Gerard E Dufour
Howard J Cohen
Bruce H Rosen
Michael S Chalup
Jennifer L Hillman
Anissa Lee Jones
Jimmy Y Yu
Lila B Greenawalt
Scott R Panzer
Ann M Roseberry
Rachel J Wright
Susan E Daniels
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, David M Hodgson, Stephen E Lincoln, Frank D Russo, Peter A Spiro, Steven C Banville, Shawn R Bratcher, Gerard E Dufour, Howard J Cohen, Bruce H Rosen, Michael S Chalup, Jennifer L Hillman, Anissa Lee Jones, Jimmy Y Yu, Lila B Greenawalt, Scott R Panzer, Ann M Roseberry, Rachel J Wright, Susan E Daniels filed Critical Incyte Genomics Inc
Priority to AU53194/00A priority Critical patent/AU5319400A/en
Priority to CA002374822A priority patent/CA2374822A1/fr
Priority to EP00938108A priority patent/EP1181357A2/fr
Publication of WO2000075298A2 publication Critical patent/WO2000075298A2/fr
Publication of WO2000075298A3 publication Critical patent/WO2000075298A3/fr
Publication of WO2000075298A8 publication Critical patent/WO2000075298A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polynucléotides (mddt.) purifiés de molécules de traitement et de détection de maladies. Elle porte également sur les polypeptides (MDDT) codés par mddt ainsi que sur l'utilisation de mddt, de compléments, d'oliugonucléotides ou de fragments de ceux-ci, dans des analyses diagnostiques. Elle se rapporte encore à des vecteurs et à des cellules hôtes contenant mddt, pour l'expression de MDDT. Elle concerne enfin l'utilisation de MDDT isolé et purifié, pour l'induction d'anticorps et pour le criblage de banques de composés ainsi que l'utilisation d'anticorps anti-MDDT dans des analyses diagnostiques. Des jeux ordonnés de microéchantillons de mddt ainsi que leurs procédés d'utilisation sont également décrits.
PCT/US2000/015344 1999-06-03 2000-06-01 Molecules pour la detection et le traitement de maladies WO2000075298A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU53194/00A AU5319400A (en) 1999-06-03 2000-06-01 Molecules for disease detection and treatment
CA002374822A CA2374822A1 (fr) 1999-06-03 2000-06-01 Molecules pour la detection et le traitement de maladies
EP00938108A EP1181357A2 (fr) 1999-06-03 2000-06-01 Molecules pour la detection et le traitement de maladies

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US13741299P 1999-06-03 1999-06-03
US60/137,412 1999-06-03
US14754299P 1999-08-05 1999-08-05
US14750199P 1999-08-05 1999-08-05
US14750099P 1999-08-05 1999-08-05
US60/147,500 1999-08-05
US60/147,501 1999-08-05
US60/147,542 1999-08-05

Publications (3)

Publication Number Publication Date
WO2000075298A2 WO2000075298A2 (fr) 2000-12-14
WO2000075298A3 true WO2000075298A3 (fr) 2001-09-20
WO2000075298A8 WO2000075298A8 (fr) 2001-11-15

Family

ID=27495267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015344 WO2000075298A2 (fr) 1999-06-03 2000-06-01 Molecules pour la detection et le traitement de maladies

Country Status (4)

Country Link
EP (1) EP1181357A2 (fr)
AU (1) AU5319400A (fr)
CA (1) CA2374822A1 (fr)
WO (1) WO2000075298A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US6664084B2 (en) * 2001-02-26 2003-12-16 Applera Corporation Isolated nucleic acid molecules encoding human glucuronyltransferase proteins, and related products and processes
CA2448116A1 (fr) * 2001-05-25 2002-12-05 Incyte Genomics, Inc. Molecules de detection et de traitement de maladies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033551A2 (fr) * 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions et procedes de diagnostic, de prevention et de traitement de la croissance et de la proliferation de cellules neoplasiques
WO1998025959A2 (fr) * 1996-12-11 1998-06-18 Chiron Corporation Proteines humaines secretees
WO1998056951A1 (fr) * 1997-06-11 1998-12-17 Abbott Laboratories Reactifs et procedes utiles dans la detection de maladies pulmonaires
WO1999002724A2 (fr) * 1997-07-11 1999-01-21 Mount Sinai Hospital Corporation Procede d'identification de genes exprimes dans des lignees selectionnees et nouveaux genes identifies au moyen de ces procedes
WO1999050405A1 (fr) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033551A2 (fr) * 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions et procedes de diagnostic, de prevention et de traitement de la croissance et de la proliferation de cellules neoplasiques
WO1998025959A2 (fr) * 1996-12-11 1998-06-18 Chiron Corporation Proteines humaines secretees
WO1998056951A1 (fr) * 1997-06-11 1998-12-17 Abbott Laboratories Reactifs et procedes utiles dans la detection de maladies pulmonaires
WO1999002724A2 (fr) * 1997-07-11 1999-01-21 Mount Sinai Hospital Corporation Procede d'identification de genes exprimes dans des lignees selectionnees et nouveaux genes identifies au moyen de ces procedes
WO1999050405A1 (fr) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 10 June 1997 (1997-06-10), HILLIER ET AL.: "Homo sapiens cDNA clone IMAGE:782683", XP002158363 *
DATABASE EMBL 18 April 1997 (1997-04-18), ADAMS ET AL.: "EST180883 JURKAT T-CELLS V HOMO SAPIENS cDNA 5'END", XP002158362 *
DATABASE EMBL 24 June 1998 (1998-06-24), NCI-CGAP: "Homo sapiens cDNA clone IMAGE:1650050", XP002158361 *
DATABASE EMBL 3 June 1997 (1997-06-03), HILLIER ET AL.: "Homo sapiens cDNA clone IMAGE:774038", XP002158360 *

Also Published As

Publication number Publication date
WO2000075298A8 (fr) 2001-11-15
CA2374822A1 (fr) 2000-12-14
EP1181357A2 (fr) 2002-02-27
WO2000075298A2 (fr) 2000-12-14
AU5319400A (en) 2000-12-28

Similar Documents

Publication Publication Date Title
WO2002079449A3 (fr) Molecules permettant de detecter et de traiter des maladies
WO2004023973A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2000073509A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO1998050554A3 (fr) POLYNUCLEOTIDES ET POLYPEPTIDES D'$i(ENTEROCOCCUS FAECALIS)
WO2000073801A3 (fr) Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
WO1997033909A3 (fr) Composes et methodes d'immunotherapie et d'immunodiagnostic pour le cancer de la prostate
WO2002083876A3 (fr) Molecules secretoires
WO2001004264A3 (fr) Genes associes a l'atherosclerose
WO2000078968A3 (fr) Sequences nucleotidiques du genome de branhamella catarrhalis
WO2000020587A3 (fr) Antigenes associes au cancer et leurs utilisations
WO2002040715A8 (fr) Molecules permettant la detection et le traitement de maladies
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2002020756A3 (fr) Molécules sécrétoires
WO2002012338A3 (fr) Procede de criblage
WO2003062376A3 (fr) Molécules pour le diagnostic et la thérapeutique
WO2001062922A3 (fr) Molecules destinees a la detection et au traitement de maladies
WO2003062379A3 (fr) Molecules pour la detection et le traitement de maladies
CA2127117A1 (fr) Adn codant un recepteur de serotonine humain 5ht4b et son utilisation
WO2002055738A3 (fr) Molecules pour la detection et le traitement de maladies
WO2004066933A3 (fr) Compositions et methodes permettant de traiter le cancer au moyen de igsf9 et de liv-1
WO2000075298A3 (fr) Molecules pour la detection et le traitement de maladies
WO2002020754A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001062927A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001062918A3 (fr) Molecules secretoires
WO2001023538A3 (fr) Molecules de detection et de traitement de maladies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
ENP Entry into the national phase

Ref document number: 2374822

Country of ref document: CA

Ref country code: CA

Ref document number: 2374822

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10009416

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000938108

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000938108

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000938108

Country of ref document: EP